TY - JOUR
T1 - Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for japanese patients with advanced non-squamous non-small-cell lung cancer-a retrospective analysis
AU - Yamaguchi, Teppei
AU - Nakanishi, Toru
AU - Hayashi, Masamichi
AU - Uozu, Sakurako
AU - Okamura, Takuya
AU - Morishita, Mariko
AU - Takeyama, Tomoko
AU - Minezawa, Tomoyuki
AU - Morikawa, Sayako
AU - Niwa, Yoshikazu
AU - Mieno, Yuki
AU - Kato, Atsushi
AU - Hoshino, Tami
AU - Isogai, Sumito
AU - Okazawa, Mitsushi
AU - Imaizumi, Kazuyoshi
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advnced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regicnen in Japanese patients in a daily clinical setting. Methods: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m2) and pernetrexed (500 mg/m2) as a first-line treatment for advanced non-squamous NSCLC. Results: Recorded Grade 3 or 4 hernatological toxicities included neutropenia in 7 cases (17.5%), leukopenia in 5 cases (12.5%), anernia in 1 case (2.5%), thrombocytopenia in 1 case (2.5%), and febrile neutropenia in 1 case (2.5%). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5%), infection in 1 case (2.5%), rash in 1 case (2.5%), and increased transaminase expression in 1 case (2.5%). Therefore, the adverse events were mostly mild. There were no treatment- related deaths. The overall response rate was 37.5%, median progression free survival was 5.6 months, and median overall suMval (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n28) was 16.8 months. Conclusion: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.
AB - Background: Cisplatin plus pemetrexed is considered the standard of care for the first-line treatment of patients with advnced non-squamous non-small-cell lung cancer (NSCLC). However, little is known about the efficacy and safety of this regicnen in Japanese patients in a daily clinical setting. Methods: We retrospectively analyzed 40 patients who received cisplatin (75 mg/m2) and pernetrexed (500 mg/m2) as a first-line treatment for advanced non-squamous NSCLC. Results: Recorded Grade 3 or 4 hernatological toxicities included neutropenia in 7 cases (17.5%), leukopenia in 5 cases (12.5%), anernia in 1 case (2.5%), thrombocytopenia in 1 case (2.5%), and febrile neutropenia in 1 case (2.5%). Grade 3 or 4 nonhematological toxicities included anorexia in 3 cases (7.5%), infection in 1 case (2.5%), rash in 1 case (2.5%), and increased transaminase expression in 1 case (2.5%). Therefore, the adverse events were mostly mild. There were no treatment- related deaths. The overall response rate was 37.5%, median progression free survival was 5.6 months, and median overall suMval (OS) was 18.8 months. In an epidermal growth factor receptor (EGFR) mutation status subgroup analysis, the median OS of patients with wild-type EGFR or unknown status (n28) was 16.8 months. Conclusion: Cisplatin plus pemetrexed was well tolerated as a first-line treatment and effective in Japanese patients with advanced non-squamous NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=84930027058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930027058&partnerID=8YFLogxK
M3 - Article
C2 - 25743136
AN - SCOPUS:84930027058
SN - 0385-0684
VL - 42
SP - 183
EP - 187
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 2
ER -
